

Due to the fact that Dr. Gular was unable to attend the meeting, this conflict of interest waiver for Dr. Gular is null and void.



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Padma Gulur, MD**

Committee: **Pharmacy Compounding Advisory Committee (PCAC)**

Meeting Date: **June 8, 2022**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda items described below, I may be considered for participation in the advisory committee meeting.

On June 8, 2022, the committee will discuss bulk drug substances nominated for inclusion on the 503A Bulk List. The nominators of these substances or another interested party will be invited to make a short presentation supporting the nomination. The three bulk drug substances to be discussed relevant to this waiver are ammonium tetrathiomolybdate (uses are evaluated for Wilson disease, use as copper (Cu) chelation therapy for the treatment of breast cancer, kidney cancer, prostate cancer, colorectal cancer, esophageal cancer, and malignant pleural mesothelioma); enclomiphene citrate (to increase serum testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to normal levels in the treatment of secondary hypogonadism); and ferric subsulfate (for use as an astringent and hemostatic agent during minor surgical procedures).

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
Stocks/investments	Stock holdings in [redacted] ^{PPI} party to the matter for ammonium tetrathiomolybdate	\$10,000 - 25,000
Stocks/investments	Stock holdings in [redacted] ^{PPI} competing firm for enclomiphene citrate and ferric subsulfate	\$25,000 - 50,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/s/ _____
Signature

5/13/22 _____
Date